SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir

 SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir

Shots:

  • Chimerix to receive $5M up front, up to $150M as clinical, regulatory & commercial milestone with royalties on global sales of Brincidofovir. SymBio to get exclusive WW rights to develop, manufacture & commercialize Brincidofovir in all human indications excluding prevention and treatment of smallpox and is responsible for all development, manufacturing & commercialization activities
  • The collaboration will allow Chimerix to focus on the development of Dociparstat sodium (CX-01) in a P-III study as a 1L treatment for AML and provide an opportunity to participate in the value of ongoing development of Brincidofovir through milestones & royalties
  • Chimerix’s Brincidofovir (BCV, CMX001) is an anti-viral therapy being developed for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections and is a prodrug of cidofovir

Click here to­ read full press release/ article | Ref: Chimerix | Image: Pappas Capital

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post